NCT04579211View on ClinicalTrials.gov

Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening

Enrolling by invitationOBSERVATIONAL
Enrollment

220

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

April 1, 2025

Study Completion Date

May 1, 2026

Conditions
Cystic Fibrosis
Interventions
DIAGNOSTIC_TEST

urine lipoarabinomannan (LAM)

Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.

Trial Locations (1)

80206

National Jewish Health, Denver

All Listed Sponsors
lead

Jerry A. Nick, M.D.

OTHER